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We report here a case of partial response to hepatic arterial infusion chemotherapy in a patient who developed serious
hepatic failure due to unresectable colorectal cancer and hepatic metastasis and showed resistance to systemic
chemotherapy with molecular targeted drugs, mFOLFOX6, and FOLFIRI. The patient was a 60-year-old woman who
underwent sigmoidectomy for sigmoid colon cancer, lateral posterior hepatic segmentectomy for metastatic liver
cancer, and postoperative radiation therapy for metastatic lung cancer. As first-line systemic chemotherapy, mFOLFOX6
(oxaliplatin, 5-fluorouracil, and leucovorin), bevacizumab + FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), and
anti-epidermal growth factor receptor antibody + irinotecan were administered, in that order. However, recurrent
hepatic metastasis was exacerbated, which induced serious hepatic failure manifested by general malaise, jaundice,
abnormal hepatic function, difficulty in walking due to bilateral lower extremity edema, and decreased appetite. The
patient was admitted in a serious condition. After hospitalization, the patient received hepatic arterial infusion
chemotherapy with 5-fluorouracil and l-leucovorin. After two complete courses, the symptoms improved. The patient’s
performance status also improved, and she was discharged from the hospital. Four months after discharge, the patient
had continued outpatient chemotherapy and maintained excellent performance status. Although HAIC is not presently
considered an alternative to systemic chemotherapy, it is sometimes effective in patients who show resistance to
molecular targeted drug therapy, FOLFOX, and FOLFIRI, and in whom hepatic metastasis is a key factor in determining
prognosis and serious hepatic failure. Further studies should be performed in the future to verify these findings.
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The Japanese guidelines for colorectal cancer treatment
and the National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines in Oncology for Colon
and Rectal Cancers recommend systemic administration
of l-leucovorin, 5-fluorouracil, irinotecan, oxaliplatin,
bevacizumab, and anti-epidermal growth factor receptor
(EGFR) antibody for unresectable or recurrent colon
cancer [1]. However, there is no effective therapy for
patients who have developed resistance to this therapy.
We report here a case of colorectal cancer with hepatic
metastasis, which was resistant to systemic therapy, and* Correspondence: tgoi@u-fukui.ac.jp
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reproduction in any medium, provided the orserious hepatic failure, for which hepatic arterial infusion
chemotherapy (HAIC) was effective.Case presentation
The patient was a 60-year-old woman with chief complaints
of general malaise, jaundice, bilateral lower extremity
edema, and decreased appetite. At admission, she presented
with conjunctival anemia and jaundice, mild tenderness in
the right upper abdomen, a palpable liver 3 cm below the
right costal margin, and bilateral lower extremity edema.
Her body temperature was 37.8°C, and her performance
status was 3 [2]. Routine admission serum chemistry
showed a white blood cell count of 17,200/μl (normal
range = 3400 to 9600/μl), and the following concentrations:
hemoglobin, 8.1 g/dl (normal range = 13.4 to 17.6 g/dl);td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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aspartate transaminase, 105 IU/l (normal range = 13 to
34 IU/l), γ-glutamyl transpeptidase, 643 IU/l (normal
range = 12 to 60 IU/l), lactate dehydrogenase, 1,414 IU/l
(normal range = 119 to 214 IU/l), and alkaline phosphatase,
4,558 IU/l (normal range = 107 to 340 IU/l). These results
indicated a hepatic function disorder. The concentrations
of tumor markers CEA and CA19-9 were significantly
increased to 197 ng/ml (normal range = 0 to 5.0 ng/ml)
and 42.9 U/ml (normal range = 0 to 37 U/ml) respectively.
Illness and course
Sigmoidectomy, lateral and posterior hepatic segmentec-
tomy, and postoperative radiation therapy were performed
in February 2008 to treat sigmoid colon cancer, metastatic
liver cancer, and metastatic lung cancer, respectively. The
final diagnosis was of sigmoid colon cancer (6 × 4 cm),
type 2, invasion depth SE, lymph node metastasis N2,
hepatic metastasis H2, P0, M1 stage IV [3].
After surgery, starting in March 2008, 12 cycles of
mFOLFOX6 were administered as first-line chemotherapy,
according to the Japanese guidelines for unresectable
advanced colorectal cancer [4]. Follow-up computed
tomography in December 2008 showed a new unresectable
hepatic metastasis. Therefore, this therapy was replaced
with bevacizumab + FOLFIRI as second-line treatment and
12 cycles were given. Follow-up computed tomography in
December 2009 showed that the hepatic metastasis
was poorly differentiated. Therefore, anti-EGFR antibody
with irinotecan was administered as third-line treatment.
However, the recurrent hepatic metastasis was exacerbated,
and the patient developed serious hepatic failure manifested
by general malaise, jaundice, abnormal hepatic function,Figure 1 Illness and course. Sigmoidectomy, lateral posterior hepatic seg
February 2008 for the treatment of sigmoid colon cancer, metastatic liver c
FOFIRI, irinotecan, 5-fluorouracil, leucovorin; mFOLFOX6, oxaliplatin, 5-fluorodifficulty in walking due to bilateral lower extremity edema,
and decreased appetite. The patient was hospitalized in
August 2011 (Figure 1).
Clinical course
The patient showed resistance to systemic administration
of the five types of chemotherapeutic agent recommended
by the Japanese guidelines for colorectal cancer treatment
and the NCCN clinical practice guidelines in oncology for
colon and rectal cancers [1,5]. The growth of the hepatic
lesion and the abnormal hepatic function suggested that
the patient had developed serious hepatic failure. Lung
metastasis was also observed; however, this did not seem
to affect prognosis. We explained to the patient and her
family members that her condition would not be life
threatening, regardless of the multiple metastases to other
organs; however, the standard therapy was not indicated.
We also explained the possibility of discontinuing the
chemotherapy, and administering palliative care and HAIC
to control the hepatic metastasis. After obtaining informed
consent, HAIC was selected and performed. After altering
blood flow in the gastroduodenal artery and right gastric
artery during angiography, the tip of the catheter was placed
in the hepatic artery, and one course of 5-fluorouracil
(250 mg/m2) and l-leucovorin (600 mg/m2) was adminis-
tered once a week. A once-weekly infusion for 6 weeks was
defined as one course. No adverse reactions were observed
during HAIC. After two courses, computed tomography
showed decreased hepatic metastasis (Figure 2). According
to the blood test results, abnormal hepatic function had
also decreased (Figure 3). However, the levels of tumor
markers CEA and CA19-9 were not decreased (Figure 1).
On admission, the patient’s performance status was 3 [2]mentectomy, and postoperative radiation therapy were performed in
ancer, and metastatic lung cancer, respectively. CPT-11, irinotecan;
uracil, and leucovorin.
Figure 2 Abdominal computed tomography. (a) Before treatment. Metastatic lesions in both lobes of the liver were revealed. (b) After two courses
of treatment, hepatic metastasis was decreased: The metastatic lesion in the liver had reduced, and the other lesions also tended to be reduced in size.
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extremity edema and the inability to eat. After two courses
of this treatment had been completed, the lower extremity
edema disappeared, and the patient could eat and perform
household chores well. Her performance status was 0, and
she was discharged. The aforementioned conditions have
been maintained for 4 months. However, 5 months later,
the recurrent hepatic metastasis was exacerbated, and theFigure 3 Blood test results. Abnormal hepatic function had decreased. ALTpatient died of serious hepatic failure. Lung metastasis
was slightly increased; however, it did not seem to affect
prognosis.
Discussion
The Japanese guidelines for colorectal cancer treatment
and the NCCN clinical practice guidelines in oncology for
colon and rectal cancers recommend FOLFOX as the, alanine transaminase; AST, aspartate transaminase; T-Bil, total bilirubin.
Sawai et al. World Journal of Surgical Oncology 2013, 11:203 Page 4 of 4
http://www.wjso.com/content/11/1/203optimal treatment for patients with unresectable recurrent
colon cancer with hepatic metastasis, and systemic chemo-
therapy with a combination of FOLFIRI and anti-VEGF
antibody or anti-EGFR antibody. The median survival of
patients with unresectable or advanced recurrent colon
cancer who do not undergo chemotherapy has been
reported as approximately 8 months. However, owing to
recent developments in chemotherapy, median survival
has been extended to approximately 2 years [1,5]. At the
initial examination, the patient had stage IV colorectal
cancer with hepatic metastasis and lung metastasis, and
had a risk of digestive tract ileus due to the primary focus.
Therefore, the primary focus and the hepatic metastasis
were removed. Radiotherapy was performed to treat the
single lung metastasis. At that time, all lesions disappeared
on the images. However, 11 months after the operation,
unresectable recurrent hepatic metastasis developed, and
systemic chemotherapy was performed in accordance with
the clinical practice guidelines for colon and rectal cancers.
The patient’s condition was maintained for 2 years and
8 months after the therapy; however, she then developed
serious hepatic failure manifested by abnormal hepatic
function, decreased appetite, general malaise, and difficulty
in walking due to bilateral lower extremity edema due to
exacerbation of hepatic metastasis. Discontinuation of the
chemotherapy was considered, since the standard therapy
was not indicated, but the patient’s condition would not be
life threatening, regardless of multiple metastases to other
organs. Control of hepatic metastasis could prolong her
life. There are no reports of the use of HAIC to treat
patients showing resistance to systemic chemotherapy with
anti-EGFR antibody, anti-EGFR antibody, mFOLFOX6,
and FOLFIRI. However, some reports have shown that
HAIC was effective for size regression and local control of
hepatic metastasis [6,7]. Therefore, HAIC was performed
after obtaining informed consent from the patient and her
family members. No adverse reactions occurred, and
serious hepatic failure was improved. After the patient
was discharged, her quality of life improved and she could
do household chores, while currently receiving outpatient
treatment. Therefore, HAIC was effective in this case.
Recently, some studies have reported that HAIC or a
combination of HAIC and systemic chemotherapy was
effective for patients who showed resistance to systemic
chemotherapy [8-11]. HAIC has again received attention in
patients in whom hepatic metastasis is a key factor deter-
mining prognosis. In recent years, systemic chemotherapy
has seen remarkable progress.
Conclusions
Although HAIC is not presently considered an alternative
to systemic chemotherapy, it is sometimes effective in
patients who show resistance to molecular targeted drug
therapy, FOLFOX, and FOLFIRI, and in whom hepaticmetastasis is a key factor in determining prognosis and ser-
ious hepatic failure. Further studies should be performed
in the future to verify these findings.
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